Class / Patent application number | Description | Number of patent applications / Date published |
514484000 | Ring in acid moiety | 59 |
20090030074 | SYNTHESIS, POLYMORPHS, AND PHARMACEUTICAL FORMULATION OF FAAH INHIBITORS - Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for the preparation of the compound of Formula (I), characterization of polymorphs of the FAAH inhibitor, and their uses therof. | 01-29-2009 |
20090048337 | Modulation of anxiety through blockade of anandamide hydrolysis - Fatty acid amide hydrolase inhibitors of the Formula: | 02-19-2009 |
20110060040 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID - Methods of using acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof are disclosed. | 03-10-2011 |
20110130454 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - Prodrugs of alpha-2-delta ligands, pharmaceutical compositions of prodrugs of alpha-2-delta ligands, methods of making prodrugs of alpha-2-delta ligands, and methods of using prodrugs of alpha-2-delta ligands and pharmaceutical compositions of prodrugs of alpha-2-delta ligands to treat various diseases are disclosed. | 06-02-2011 |
20110263701 | GABAPENTIN ENACARBIL COMPOSITIONS - The present invention provides a stabilized composition comprising a non-crystalline gabapentin enacarbil and at least one crystallization-inhibiting compound. In particular, the present invention provides a stabilized composition of gabapentin enacarbil, wherein the gabapentin enacarbil is maintained in a non-crystalline form by the composition, for example, as an amorphous form. The invention also provides, among other things, methods of making the stabilized composition, or use of the stabilized composition for making a medicament. | 10-27-2011 |
20110313036 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 12-22-2011 |
20120010283 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS - Fatty acid amide hydrolase inhibitors of the Formula: | 01-12-2012 |
20120041061 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES - Methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel syndrome, social phobia, Parkinson's disease, asthma, cough, or chronic obstructive pulmonary disease, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel syndrome, social phobia, Parkinson's disease, asthma, cough, or chronic obstructive pulmonary disease are disclosed. | 02-16-2012 |
20130046012 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN - The present invention relates to compounds of formula (I), or pharmaceutically acceptable, stereoisomers, salts or solvates thereof | 02-21-2013 |
20130217764 | PERIPHERALLY RESTRICTED FAAH INHIBITORS - Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R | 08-22-2013 |
20140235710 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 08-21-2014 |
20140288170 | META-SUBSTITUTED BIPHENYL PERIPHERALLY RESTRICTED FAAH INHIBITORS - The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit. | 09-25-2014 |
20150353483 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 12-10-2015 |
20160024000 | Phenyl Carbamate Compounds for Use in Preventing or Treating a Movement Disorder - The present invention provides a pharmaceutical composition for preventing and/or treating a movement disorder comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating movement disorder. | 01-28-2016 |
20190144378 | MEMANTINE COMPOUNDS AND THEIR PREPARATION AND USES THEREOF | 05-16-2019 |
514485000 | The ring is a benzene ring | 44 |
20100063144 | COMPOUNDS AND USES THEREOF - There is provided a compound of formula (I) wherein R | 03-11-2010 |
20100120906 | MODIFIED RELEASE FORMULATION AND METHODS OF USE - A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), about 1.0-10% of an anionic surfactant, and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine following administration to a subject for 4-20 hours longer than the time required for in vitro release of 80% of retigabine. A formulation includes about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix, and an agent for retarding release in the gastric environment. The plasma concentration vs. time profile of this formulation is substantially flat over an extended period lasting for about 4 hours to about 36 hours. A method of treating a disorder characterized by nervous system hyperexcitability includes administering to a subject an effective amount of these pharmaceutical formulations. | 05-13-2010 |
20100130601 | INSECTICIDAL COMPOUNDS - A compound of formula (I), wherein A | 05-27-2010 |
20100261788 | Inhibition of Bid-Induced Cell-Death Using Small Organic Molecules - Various phenylamine derivatives are described as well as the use of compounds to inhibit BID protein for controlling apoptotic cascade. | 10-14-2010 |
20120016020 | SOLID DISPERSION OF ALPHA-KETOAMIDE DERIVATIVES - A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability. | 01-19-2012 |
20120122973 | DRY PROCESSING OF RETIGABINE - The invention relates to dry processes for the production of oral dosage forms, especially tablets, containing retigabine and adhesion promoter. In addition, the invention relates to compacted intermediates containing retigabine and an adhesion promoter. Finally, the invention relates to single-dose and multiple-dose containers, preferably sachets and stick-packs, containing the intermediate of the invention. | 05-17-2012 |
20120172426 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives - The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 07-05-2012 |
20130079399 | NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES - The present invention refers to the compounds corresponding to the following general formula (I): | 03-28-2013 |
20130109751 | LSD-1 ENZYME INHIBITORS FOR INDUCING OSTEOGENIC DIFFERENTIATION | 05-02-2013 |
20130131164 | STABILIZED PHENYLCARBAMATE DERIVATIVE IN SOLID STATE - The invention relates to retigabine with improved color quality, and to processes for preparing the same. In addition, the invention relates to a process for drying wet retigabine. Also, the invention relates to stabilized or substantially stabilized retigabine in solid state, or a mixture or pharmaceutical formulation comprising the same. Further, the invention also relates to an improved process for preparing retigabine. | 05-23-2013 |
20130267590 | RETIGABINE COMPOSITIONS - Stable premixes comprising retigabine, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier, and process for preparing the same are disclosed. Stable premixes comprising retigabine, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable inorganic carrier, and processes for preparing the same and incorporating them in compositions that are employed for therapeutic uses and methods of treatment. | 10-10-2013 |
20140024709 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES - The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 01-23-2014 |
20140066500 | CYCLOALKYLMETHYLAMINES - The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 03-06-2014 |
20160002155 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B - Inhibitors of HBV replication of Formula (I) | 01-07-2016 |
20160106691 | CHEMICAL CHAPERONINS AS NOVEL MOLECULAR MODULATORS OF BETA PROTEIN AGGREGATION PRESENT IN CONFORMATIONAL DISEASES - This invention relates to chemistry and biochemistry applied to the field of medicine and is referred to a new method of prevention and therapeutic treatment of conformational diseases (CD), in particular to amyloid origin diseases by administrating an effective amount of one or more compounds, salts, prodrugs or solvates, which are considered herein as chemical chaperonins, of Formula I, | 04-21-2016 |
20160129020 | METHOD FOR TREATING RECURRING SKIN AND MUCOUS MEMBRANE DISEASES CAUSED BY HSV-1 AND HSV-2 - The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH | 05-12-2016 |
20170232010 | DRUG WITH ACTIVITY AGAINST THE HERPES VIRUS FAMILY | 08-17-2017 |
514486000 | Phenoxy in acid moiety | 4 |
20090326059 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - The present invention relates to benzyloxyanilide derivatives having the following structural formula: | 12-31-2009 |
20120059055 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 03-08-2012 |
20120329869 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS - The present invention relates to benzyloxyanilide derivatives having the following structural formula: | 12-27-2012 |
20130231386 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES - The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications. | 09-05-2013 |
514487000 | The benzene ring is attached to nitrogen through an acyclic carbon or carbon chain | 19 |
20090118365 | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain - Methods of treating neuropathic pain, musculoskeletal pain, and back spasm associated with musculoskeletal pain in a patient comprising orally administering a therapeutically effective dose of a prodrug of a GABA | 05-07-2009 |
20090281178 | Compounds for Lysosomal Modulation and Methods of Use - Compounds useful for promoting lysosomal processes and thereby ameliorating the disruption of cellular and functional integrity induced by Aβ and other protein and glycoconjugate species are provided. Methods for the treatment of neurodegenerative diseases that involve protein accumulation and aggregation in the brain, such as Alzheimer's, Parkinson's and Huntington's Disease, are also provided. | 11-12-2009 |
20100113591 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 05-06-2010 |
20110098352 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases. | 04-28-2011 |
20120016021 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS - Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and other forms of mental retardation, and/or autism comprising administering a GABA | 01-19-2012 |
20120046358 | USE OF ISOTHIOCYANATES COMPOUNDS IN TREATING PROSTATIC DISEASES AND SKIN CANCER - A method for preventing and treating prostatic diseases and skin cancer using naturally or artificially synthesized isothiocyanates compounds or the derivatives or metabolites thereof. | 02-23-2012 |
20130005801 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME - A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided. | 01-03-2013 |
20130041026 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE - Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed. | 02-14-2013 |
20130116318 | Enzyme Inhibitors - Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: | 05-09-2013 |
20130184338 | PHENYLPROPYL CARBAMATE DERIVATIVES FOR USE IN PREVENTING OR TREATING MULTIPLE SCLEROSIS - A phenyl carbamate compound, and a method of treating and/or preventing multiple sclerosis comprising administering a pharmaceutically effective amount of the phenyl carbamate compound to a subject in need of treating and/or preventing multiple sclerosis, are provided. | 07-18-2013 |
20130203846 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ALS - A composition for treating and/or preventing ALS containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or preventing ALS comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of ALS treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or preventing ALS, are provided. | 08-08-2013 |
20140051753 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME - A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided. | 02-20-2014 |
20140066501 | Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use - Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed. | 03-06-2014 |
20140275243 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES - The present invention provides a pharmaceutical composition for preventing and/or treating a pediatric epilepsy or epilepsy-related syndrome comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating pediatric epilepsy or pediatric epilepsy-related syndromes. | 09-18-2014 |
20140296334 | N-Optionally Substituted Aryl-2-Oligomer-3-Alkoxypropionamides - The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 10-02-2014 |
20150133541 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME - A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided. | 05-14-2015 |
20150313865 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE - Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed. | 11-05-2015 |
20160016896 | Phenyl Carbamate Compound and a Composition for Preventing or Treating a Memory Loss-Related Disease Comprising the Same - The present invention relates to a composition for preventing or treating a memory loss related disease comprising a phenyl carbamate compound and a method for preventing or treating various diseases related to loss of memory therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating memory loss-related diseases such as dementia and Alzheimer's disease. | 01-21-2016 |
20160144047 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES - The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 05-26-2016 |
514488000 | Ring in alcohol moiety | 4 |
20090082435 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders - Methods, compositions, and compounds for inhibiting monoacyglycerol lipase, and for treating pain, for modulating stress-induced analgesia or for treating stress-induced disorders in mammals are provided. | 03-26-2009 |
20120225937 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PG12 RECEPTOR AGONISTS - The present invention relates to salts of 2-(2-((4-(((4-chlorophenyl)(phenyl)-carbamoyloxy)methyl)cyclohexyl)methoxy)acetamido)ethanesulfonic acid (Compound 1) and crystalline forms, solvates and hydrates thereof. The present invention further relates to processes and intermediates useful in the preparation of Compound I and salts, solvates and hydrates thereof. Crystalline forms, salts, solvates and hydrates of the present invention and pharmaceutical compositions thereof are useful in the treatment of for example, pulmonary arterial hypertension (PAH); platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; atherosclerosis; acne; type I diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD). | 09-06-2012 |
20130261178 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES - A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: | 10-03-2013 |
20140249216 | METHODS OF TREATMENT USING MODULATORS OF SIRT2 - The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2, with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2, and kits for practicing the assay method. | 09-04-2014 |